Close

SAB Biotherapeutics (SABS) Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. META
2. CMG
3. IBM
4. HCP
5. PI
6. LRCX
7. CNMD
8. BSX
9. BIIB
10. F


Go back to SAB Biotherapeutics (SABS) Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus

SAB Biotherapeutics (SABS) Halted, News Pending

December 1, 2021 6:55 AM EST

SAB Biotherapeutics (NASDAQ: SABS) Halted, News Pending

... More